For Immediate Release: February 14, 2018
513-579-9911 x 12627
Medpace and Cincinnati Children’s to Present Webinar on Rare Disease Day:
Getting Treatment Options to Rare Disease Patients Faster – Putting Patients First in Clinical Trials
CINCINNATI, OH — (February 14, 2018) – Medpace (MEDP), a scientifically-driven, global full service clinical research organization (CRO) known for its strong therapeutic and regulatory expertise, and Cincinnati Children’s Hospital Medical Center, one of the nation’s leaders in pediatric healthcare, announced that they will be presenting a complimentary webinar to highlight the importance of patient-centric clinical research. The webinar will air on February 28 – the nationally recognized Rare Disease Day which takes place on the last day of February each year where the main objective is to raise awareness amongst the general public and decision makers about rare diseases and their impact on patient lives. In the webinar detailed below, Medpace and Cincinnati Children’s will discuss how patient-focused clinical trial design and collaborative approaches to site enrollment can accelerate clinical research. They will be joined by Beth Woelfel Harvey, a parent of a child with Duchenne muscular dystrophy, who will bring the patient and care giver perspective to this important topic.
“In our work with prestigious research sites like Cincinnati Children’s Hospital Medical Center, we are acutely aware of the challenges for both researchers and patients in the rare disease indications,” commented Susan Burwig, Executive Vice-President, Operations at Medpace. “Open dialogue and communication with patient advocacy groups, sites and the patients and their families, is paramount to accelerating treatments and we are proud to be an active participant in that conversation.”
“Rare diseases affect more than 30 million people in the United States alone, and more than half of those are children,” said Margaret Hostetter, MD, chief medical officer and director, Cincinnati Children’s Research Foundation. “With the vast majority of rare diseases having no FDA-approved therapy, Cincinnati Children’s is in a unique position to help. By investing in the development of new therapies, and by ensuring that patients have access to appropriate treatment options in a timely manner, we can help lessen the burden felt by patients and their families.”
Getting Treatment Options to Rare Disease Patients Faster:
Putting Patients First in Clinical Trials
DATE: Wednesday February 28, 2018
TIME: 11am EST (NA) / 4pm GMT (UK) / 5pm CET (EU-Central)
DURATION: 60 minutes
For more information about Rare Disease Day, visit the website at: https://www.rarediseaseday.org/
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 2,500 people across 35 countries.
About Beth Harvey and JB’s Keys to DMD
Beth Woelfel Harvey is a parent of a child with Duchenne muscular dystrophy (DMD). She is the founder and Executive Director of the organization JB’s Keys to DMD, named after her son. She started the organization to help raise awareness of DMD while appropriating funds for quality care and experiences, ensuring affected children will have the opportunities of a lifetime.